%0 Journal Article
%T Pretreatment SUVmax value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
%A Cengiz Gemici
%A Gokhan Yaprak
%A Melike Ozcelik
%A Ozgur Seseogullari
%J Archive of "Northern Clinics of Istanbul".
%D 2019
%R 10.14744/nci.2019.02212
%X Stage III disease accounts for approximately one-fourth of all non-metastatic non-small cell lung cancer (NSCLC). The patients who are not candidates for curative resection are offered concomitant chemoradiotherapy. In this subgroup, which is difficult to manage, studies that address the role of PET-CT to predict outcome measures specifically for stage III NSCLC receiving concurrent chemoradiotherapy may help better risk stratification. This study aimed to assess whether baseline PET maximum standardized uptake value (SUVmax) value in stage III NSCLC treated with concurrent chemoradiotherapy would independently identify patients with high risk of progression and death
%K Chemoradiotherapy
%K PET scan
%K stage III NSCLC
%K SUVmax
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593921/